

Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway

Xiao-Fei Song^{1,2} · Qi-Hua Wang² · Ran Huo¹

Received: 10 July 2017 / Accepted: 18 October 2017 / Published online: 14 November 2017
© Arányi Lajos Foundation 2017

Abstract This study was conducted in order to elucidate the role microRNA-708 (miR-708) plays between proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) involving melanoma cells by targeting using LEF1 through the Wnt signaling pathway. Male Kunming mice were selected and subsequently divided into normal and model groups to take part in this study. Following cell line selection, the B16 cells with the highest miR-708 expression were selected and assigned into the control, blank, negative control (NC), miR-708 mimic, miR-708 inhibitor, siRNA-LEF1, and miR-708 inhibitor + siRNA-LEF1 groups. A Bioinformatics Web service and dual-luciferase reporter assay were conducted in order to determine the relationship between LEF1 and miR-708. The RT-qPCR method was performed in order to detect the miR-708 expression and mRNA expressions of LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3, E-cadherin, and western blotting was used in order to detect the protein expressions of these genes. MTT assay, scratch test, Transwell assay, and flow cytometry were all conducted in order to detect the cell proliferation, migration, invasion, and cycle/apoptosis, respectively. LEF1 was verified as the target gene of miR-708. In comparison with the normal group, the model group had reduced expressions of miR-708, Bax, Caspase3, and E-cadherin, while showing elevated expressions of LEF1, β -catenin, Bcl-2, Wnt3a,

and N-cadherin. In comparison to the blank and control groups, the miR-708, mimic, and siRNA-LEF1 groups had elevated expressions of Bax, Caspase3, and E-cadherin, while also showing enhanced cell apoptosis. The miR-708, mimic, and siRNA-LEF1 groups also had decreased expressions of LEF1, β -catenin, Bcl-2, Wnt3a, and N-cadherin, and reduced optical density value 48 h and 72 h after transfection. Besides, these two groups showed declined cell migration and invasion, as well as lengthened G0/G1 phase (increased cell number) and shortened S phase (decreased cell number). Our findings demonstrated that an overexpressed miR-708 inhibits the proliferation, invasion, migration, and EMT, but also promotes the apoptosis of melanoma cells by targeting LEF1 through the suppression of the Wnt signaling pathway.

Keywords MicroRNA-708 · Epithelial-mesenchymal transition · Melanoma cells · Lymphoid enhancer-binding factor-1 · Wnt signaling pathway

Introduction

Melanoma is a kind of cutaneous cancer that has shown an elevating prevalence worldwide and a high mortality rate stemming from being metastatic or during unresectable stages [1]. Among known cancers, Melanoma harbors the highest number of the mutations per tumor [2]. As a rare skin cancer, it develops from the malignant transference of melanocytes as well as has the fastest growing incidence among all cancers in men as well as the second growing incidence in women [3]. If recognized and treated early, most melanoma remains curable. However, once metastasized, melanoma will be difficult to cure and attributes to 80% of deaths in association with other skin cancers [4]. The efficiency of the treatment of metastatic

✉ Ran Huo
huoran8003@163.com

¹ Department of Aesthetic Plastic and Burn Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwuweiqi Road, Jinan 250021, People's Republic of China

² Department of Dermatology, Linyi Dermatology Hospital, Linyi 276003, People's Republic of China

melanoma has shown no remarkable increase in the past 50 years, along with the 5-year survival rate never exceeding 5% [5]. Recently, melanoma treatment has seen a significant change with the appearance of targeted immunotherapies [6]. An essential approach to melanoma treatment is the usage of BRAF and MEK inhibitors, such as dabrafenib, vemurafenib, trametinib, and cobimetinib [7]. Importantly, microRNAs (miRs) are indicated in both the pathogenesis and progression of the melanoma, including the tumor suppressor, miR-let7b which can target cyclin D as well as regulate the cell cycle [8].

MiRs are involved in various different cellular processes and are often categorized into two kinds, oncogenic and tumor suppressor miRs and miRs are also reported to be involved in the development and progression of melanoma [9–11]. MiR-708 has been confirmed and identified as one of the prevalent suppressed miRs in hepatocellular carcinoma (HCC) tissues and in vitro, the enforced miR-708 expression inhibits the invasion and migration of HCC cell lines [12]. Restoration of the miR-708 expression in renal cell carcinoma (RCC) cell lines can also lead to a decrease in cell clonality, growth, invasion, as well as migration and ultimately results in a significant increase in cell apoptosis [13]. Clinically, lower miR-708 expressions have been found in the late stage of the ovarian tumors in comparison with normal patients and patients who have high miR-708 have a better survival rate, indicating that miR-708 serves as a therapeutic modality in the metastatic ovarian epithelial cancer [14]. Lymphoid enhancer-binding factor-1 (LEF1) is one of the 48-kD nuclear proteins that is often expressed in the T and pre-B cells and is also a very significant member of the Wnt/ β -catenin in embryonic stem cells [15]. Interestingly enough, melanoma cells can make use of various kinds of resistance mechanisms, such as the reactivation of mitogen-activated protein kinase (MAPK) signaling pathway [16] as well as aberrant activation of another signaling pathway, the Wnt signaling pathways [17, 18]. Thus, this study aims to explore the role between miR-708 and proliferation, invasion, migration, EMT, and apoptosis of melanoma cells by targeting LEF1 by way of the Wnt signaling pathway.

Materials and Methods

Study Subjects

In total, 40 clean male Kunming mice (6–9 weeks, 16–24 g) were selected and obtained from the Animal experiments Center of the Southern Medical University in order to conduct this experiment. One week before commencement of the experiments, the mice were purchased to adapt to a certain environment with a humidity between 50%–60% at temperatures ranging from 22–24 °C in a day/night cycle of both 12 h. The mice were provided water and food during these

cycles. All mice were randomly assigned into the normal ($n = 20$) and model ($n = 20$) groups, while the mice in the model group were used for the establishment of the melanoma model. All experiments were conducted in accordance with the management of the local animal and the Declaration of Helsinki.

Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) for Melanoma Cell Line Selection

Four melanoma cell lines, namely B16, A375, WM239, and WM451 cell lines were all purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. All of the cells above were put into the RPMI 1640 medium (SP1355, Shanghai Shifeng biological technology Co., Ltd., Shanghai, China) containing a 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin were conventionally cultured in a 5% CO₂ incubator (DHP-9162, Shanghai Jicheng experimental instrument Co., Ltd., Shanghai, China) at a temperature of 37 °C with a saturated humidity and constant temperature. The fresh medium was changed every 1–2d. When the cell confluence reached 80%–90%, the subculture was subsequently conducted. The third generation cells were used in order to conduct the miR-708 quantitative detection for cell line selection. The Trizol kit (15596–018, Invitrogen, New York, California, USA) was used in order to extract the total RNA of the B16, A375, WM239, and WM451 cell lines. Following that, the nanodrop ultraviolet spectrophotometer (2000, Thermo, Waltham, Massachusetts, USA) was performed in order to determine the ratio of the absorbance (A) 260/A280 and RNA concentration of the extracted RNA. The cell samples were then reserved at a temperature of -80 °C for further use. The reverse transcription kit (RR037A, Takara Holdings Inc., Kyoto, Japan) was adapted in order to prepare the cDNA. The RT-qPCR RNA detection kit was purchased from the Ambion (Austin, Texas, USA) and the following AM 1005 fluorescence PCR (AM1005, Invitrogen, New York, California, USA) was conducted for the reaction. The reaction conditions for the miR-708 were as follows: pre-denaturation at a temperature of 95 °C for 3 min, 35 cycles of denaturation at a temperature of 95 °C for 15 s, annealing at a temperature of 60 °C for 30s and an extension at a temperature of 60 °C for 30s. The miR-708 was also quantified with the U6 as the internal reference. The primers were synthesized by the Shanghai Boya Biotech Co., Ltd. (Shanghai, China). The solubility curve was adapted in order to evaluate the reliability of the obtained PCR results. The Ct value was obtained and the $2^{-\Delta\Delta Ct}$ method was used in order to calculate the relative expression of the target gene [19]. The formula was presented as below: $\Delta\Delta Ct = [Ct_{(target\ gene)} - Ct_{(reference\ gene)}]_{experimental\ group} - [Ct_{(target\ gene)} - Ct_{(reference\ gene)}]_{control\ group}$.

Melanoma Model Establishment by Subcutaneous Implantation of B16 Cells

The eye scissors were used carefully in order to snip the interior side of both the left and right limb of the mice with no subsequent damage and the skin was disinfected using a 75% ethyl alcohol. The B16 cell line was taken out and the cell number was adjusted at a rate of 1×10^5 . The 0.2 mL of cell suspension was seeded in the interior side of both left and right limbs of the mice. The animals were then sacrificed and the tumor was stripped when the oncocyte grew into a tumor with a diameter reaching up to almost 0.6 cm.

Hematoxylin-Eosin (HE) Staining

The melanoma and normal tissues were obtained, fixed by a solution of 3% neutral formaldehyde, dehydrated using a gradient ethanol, cleared in xylene, embedded with paraffin, and sliced conventionally in order to obtain specimens with a thickness of 5~8 μm . HE staining was performed following dewaxing. After dehydration and transparent treatment saved for another time, the slices were then sealed by the neutral balsam in order to make the specimens.

Immunohistochemistry

The expression of LEF1 protein was determined using the immunohistochemical substance P (SP) method. The samples were fixed using a 10% formaldehyde, sectioned with paraffin, and finally dewaxed. The Antigens were repaired using microwaves. The samples were treated with endogenous interruption by interference of peroxidase and sealed by using a normal goat serum solution. Next, the primary antibody, namely the rabbit anti-mouse LEF1 antibody (1:1000, ab217378, Abcam, Cambridge, MA, USA), was added in order to incubate the sections at a temperature of 4 °C overnight, followed by rinsing using PBS. Following this step, the secondary antibody horseradish peroxidase (HRP)-labeled goat anti-rabbit antibody (DF7852, Shanghai Yao Yun Biotechnology Co., Ltd., Shanghai, China) was then added into the samples to incubate for 30 min at room temperature. The sections were then colored using diaminobenzidine (DAB, ab64238, Abcam, Cambridge, MA, USA), re-stained using hematoxylin and then sealed. The PBS, instead of the primary antibody, was used as the negative control solution and the normal mucous membrane as the positive control solution. The Nikon imaging analysis software (Nikon Corporation, Kanagawa, Japan) was used in order to calculate the positive cell count, while 5 high power fields ($\times 200$) were selected randomly for each section. Each field had, in total, 200 cells and the positive cell number in the field was calculated along with the mean positive expression rate. The

formula went as follows: the average positive expression rate = (positive cell number/total cell number) \times %.

Cell Grouping and Transfection

The cells assignments went as follows: the control (normal), blank (no transfected sequences), negative control (NC, transfected with the NC sequence of the miR-708), miR-708 mimic (transfected with the miR-708 mimic), miR-708 inhibitor (transfected with the miR-708 inhibitor), siRNA-LEF1 (transfected with the siRNA-LEF1), and miR-708 inhibitor + siRNA-LEF1 (transfected with the miR-708 inhibitor and siRNA-LEF1) groups. 24 h prior to cell transfection, the cells were seeded into a 6-well plate, and when the confluence reached between 30~50%, the cell transfection was then performed following the instructions of lipofectamin 2000 (11668-019, Invitrogen, New York, California, USA). After that, 250 μl Opti-MEM medium free of the serum (51,985,042, Gibco, Gaithersburg, MD, USA) was adopted for the dilution of the 100 pmol blank, NC, miR-708 mimic, miR-708 inhibitor, miR-708 inhibitor + siRNA-LEF1, and siRNA-LEF1 with a final concentration reaching 50 nM which was then evenly mixed and incubated at room temperature for 5 min. In addition, 250 μl of Opti-MEM medium free of the serum was used in order to dilute the 5 μl of lipofectamin 2000, which was then evenly mixed with and incubated at room temperature for 5 min. In succession, the two prepared solutions were then mixed together, incubated for 20 min at room temperature, added into the cell culture well for incubation in a 5% CO₂ incubator at a temperature of 37 °C for 6~8 h. The medium was then changed with the complete medium, cultured for 24~48 h and used for the remaining experiments.

RT-qPCR

The miR Neasy Mini Kit (217004, Qiagen Company, Hilden, Germany) was adopted in order to extract the total RNA contained in melanoma and normal tissues. The primers of the miR-708, LEF1, β -catenin, Wnt3a, N-cadherin, B cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), Caspase3, E-cadherin, and U6 were all designed and synthesized by the Takara Holdings Inc. (Kyoto, Japan), showing as the Table 1. The Prime Script RT kit (RR036A, Takara Holdings Inc., Kyoto, Japan) was used for RNA reverse transcription into the cDNA with a total system of 10 μl . According to the instructions, the reaction conditions were as follows: reverse transcription at a temperature of 37 °C (3 times \times 15 min), and a reverse transcriptase enzyme inactivation reaction at a temperature of 85 °C for 5 s. The reaction solution was then taken out for the quantitative fluorescent PCR following the instructions provided by the Premix Ex Taq™ II kit (RR820A, Takara Holdings Inc., Kyoto, Japan). The reaction system was in total 50 μl including 25 μl of

Table 1 The primer sequences for the RT-qPCR

Primer	Sequence
MiR-708	F: 5'-CGCGGATCCGACTTCATTCCTAACCC-3' R: 5'-CCGGAATTCTGGCACGCAGGAGACAGT-3'
LEF1	F: 5'-CATTCGGACATTCCTGGAGC-3' R: 5'-TTTGTTCCTGGCTCGAGTTT-3'
β -catenin	F: 5'-GAGCCGTCAGTGCAGGAG-3' R: 5'-CAGCTTGAGTAGCCATTGTCC-3'
Bcl-2	F: 5'-GACTTCGCCGAGATGTCCAG-3' R: 5'-CGGTGCTTGGCAATTAGTGG-3'
Wnt3a	F: 5'-ATGCCCTCAGAGATGTTGCCTCACT-3' R: 5'-TCAGATGGGTCTGAAACAACCT-3'
Bax	F: 5'-ATGGAGCTGCAGAGGATT-3' R: 5'-AATGTCCAGCCCATGATGGTTC-3'
Caspase3	F: 5'-GACTAGCTTCTTCAGAGGCGA-3' R: 5'-ATTCCGTTGCCACCTTCCTG-3'
E-cadherin	F: 5'-AGTTTACCCAGCCGGTCTTTGAG-3' R: 5'-TCGGTGGCTGAGACCTTCATC-3'
N-cadherin	F: 5'-TTTGGGGAGGGTAAAAGTTC-3' R: 5'-AAGAAACAGCCACCCCTTT-3'
GAPDH	F: 5'-GTGAAGGTCCGTGTGAACGGATT-3' R: 5'-GGTCTCGCTCCTGGAAGATGGT-3'
U6	F: 5'-GCTTCGGCAGCACATATACTAAAAT-3' R: 5'-CGCTTACGAATTTGCGTGCAT-3'

miR-708, microRNA-708; LEF1, Lymphoid enhancer-binding factor-1; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated X protein; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; RT-qPCR, Reverse transcription quantitative polymerase chain reaction; R, Reverse; F, Forward

SYBR® Premix Ex Taq™ II (2 ×), 2 μ l of PCR forward primer, 2 μ l pf PCR reverse primer, 1 μ l of ROX Reference Dye (50 ×), and 4 μ l of DNA template and 16 μ l of ddH₂O. The ABI7500 quantitative PCR instrument (7500, ABI Company, Oyster Bay, NY, USA) was also adopted for quantitative fluorescent PCR detection. The reaction conditions were as follows: pre-denaturation at a temperature of 95 °C for 30s, denaturation at a temperature of 95 °C for 5 s, annealing at a temperature of 60 °C for 30s and extension at a temperature of 60 °C for 30s, in total 40 cycles. The miR-708 relative expression level was quantified using U6 as the internal reference. The Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal reference for the LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3, and E-cadherin. The relative quantification method was used and the $2^{-\Delta\Delta Ct}$ method was also used in order to calculate the relative transcription level of the target gene (miR-708, LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin) [19]. The formula was presented below: $\Delta\Delta Ct = [\Delta Ct_{(tumor\ group)} - \Delta Ct_{(normal\ group)}]$, $\Delta Ct = Ct_{(target\ gene)} - \Delta Ct_{(internal\ reference)}$ and the mRNA expression of the target gene = $2^{-\Delta\Delta Ct}$.

Western Blotting

The RIPA kit (R0010, Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was used in order to extract the total protein in the fresh tissue and the bicinchoninic acid (BCA) method was used for calculation of the protein concentration. After protein quantification in accordance to different concentration, the protein was then separated by the polyacrylamide gel electrophoresis which was then transferred into the NC membrane, and sealed using a 5% bovine serum albumin (BSA) at room temperature for 1 h. The diluted primary antibody, namely the rabbit anti-mouse polyclonal LEF1 antibody (1:1000, ab217378), β -catenin antibody (1:5000, ab32572), bcl-2 antibody (1:500, ab692), Wnt3a antibody (1:3000, ab28472), Bax antibody (1:2000, ab32503), Caspase3 antibody (1:500, ab13847), E-cadherin antibody (1:1000, ab76055), and N-cadherin antibody (1:50,000, ab18203) were added for incubation at a temperature of 4 °C overnight. All antibodies above were purchased and obtained from the Abcam (Cambridge, MA, USA). The PBS was used for washing the membrane 5 times, (5 min for each time) followed by addition of HRP-labeled goat anti-rabbit immunoglobulin G (IgG) antibody (1:5000, Beijing Zhongshan Biotechnology Co., Ltd., Beijing, China). Finally, the membrane was soaked in the electrochemiluminescence (ECL) solution (WBKLS0500, Pierce, Rockford, IL, USA), developed in a dark room for observation, and photographed.

Bioinformatics Website and Dual-Luciferase Reporter Gene Assay

According to the website, microRNA.org, the target gene of miR-708 was analyzed in order to verify whether or not LEF1 was the target gene associated miR-708. Based on the sequences between combining 3'UTR region of LEF1 mRNA and miR-708, the target sequence and the mutation sequence were hereby designed. The target sequence was chemically synthesized with two ends being inserted into two enzyme sites Xho I and Not I, and the synthesized segments were colonized into the PUC57 vector. After identification of the positive clone, the DNA sequencing was subsequently performed in order to verify the combined plasmid. The plasmid was then sub-colonized into the psiCHECK-2 vector, which was then transferred into the bacillus coli DH5 α cells with the plasmid amplified. According to the Omega plasmid Small Dosage Kit (Omega Bio-tek Inc., Norcross, GA, USA), after the plasmid was amplified, the plasmid was then extracted. The cells were then seeded into a 6-well plate at rates of 2×10^5 cells for each well, followed by the cell transfection performance when the cells were adhered to the wall. After a successful transfection, the cells were then cultured for 48 h and then collected. The change of luciferase activity of LEF1 3'-UTR affected by miR-708 was then detected according to

the instruction given by the dual-luciferase assay kit (GeneCopoeia, Inc., Rockville, MD, USA) and the fluorescence intensity was detected using the Glomax20/20 luminometer fluorescence detector (Promega Corporation, Madison, WI, USA). The experiments in each group were repeated three more times.

3-(4, 5-Dimethylthiazol-2-Yl)-2, 5-Diphenyltetrazolium Bromide (MTT) Assay

After cell transfection transpired for 48 h, the cells in each group were collected for cell count, seeded into a 96-well plate with a density rate of $3 \times 10^3 \sim 6 \times 10^3$ cells/well, and then put into a DMEM/F12 culture medium containing 10% FBS and then cultured in an incubator with 5% CO₂ at a temperature of 37 °C (6 duplicated wells). At 24 h, 48 h, and 72 h after transfection, each well was then added with 20 µl of 5 mg/mL MTT solution in order to continue to culture for 2 h. After the supernatant was discarded, 150 µl of dimethyl sulfoxide (DMSO) was then added in each well and the enzyme-linked immunosorbent assay instrument was used in order to detect the optical value (OD) at the wavelength of 570 nm. Each experiment was repeated three times and the cell viability curve was drawn with the time point noted as the X-axis and the OD value noted as the Y-axis.

Scratch Test

After cell transfection for 48 h, the cells were then seeded in a 6-well plate, and the medium was changed using Dulbecco's modified eagle medium (DMEM) free serum when the cells adhered to the wall. When the cell confluence reached between 90%~100%, the 10 µl of gunpoint was slowly scratched in the bottle containing the 6-well plate in the vertical direction. After that, PBS rinsing was conducted 3 times. The cells were then added with DMEM culture medium containing 1% FBS and cultured in an incubator with 5% CO₂ at a temperature of 37 °C. Between 0 and 24 h, multiple fields were randomly selected in order to take pictures. The experimental results were analyzed using an Image J software. Three duplicated wells were used for each well and the experiments in each group were repeated a total of three times.

Transwell Assay

The Transwell chambers with matrigel were preheated to a temperature of 37 °C. After cell digestion and transfection, cell grouping was the same as the aforementioned method. The cells were washed 2 times using a serum-free medium and suspended using a serum-free medium. The cells were counted and the cell density was adjusted to a rate of 1×10^5 cells/ml. A total of 600 µL of RPMI 1640 culture medium containing 20% FBS was added in the lower

Transwell chamber and 200 ml cell suspension was added in the upper Transwell chamber followed by culturing at a temperature of 37 °C for a total of 48 h. Transwell chambers were taken out and the cells on the upper lateral membrane were subsequently removed. After washing using PBS, the cells were fixed with 4% poly formaldehyde solution for 10 min and stained using crystal violet. Cell staining was observed under a light microscope by use of photography. Five high-power fields were selected for the cell count. Three duplicated wells were also used for each well and experiments in each group were repeated three times, obtaining the mean value.

Flow Cytometry

After cell transfection for 48 h, the cells in each group were then collected, washed by cold PBS three times, centrifuged following the discarding of the supernatant, re-suspension by the PBS with the cell density almost adjusted to a rate of 1×10^5 cells/ml, and finally added with a temperature of -20 °C pre-cooled 75% alcohol (1 ml) for 1 h fixing at a temperature of 4 °C. Next, the cells were centrifuged again this time with the ice alcohol eliminated, washed by PBS twice in order to eliminate the supernatant, added with 100 µl of RNase A away from light, undergoing a water bath at a temperature of 37 °C for 30 min, treated with 400 µl of propidium iodide (PI, Sigma-Aldrich Chemical Company, St Louis MO, USA) and then evenly mixed. Following 30 min of incubation in the darkness at a temperature of 4 °C, the cell cycle was then detected using the red fluorescence from the excitation wavelength of 488 nm.

After cell transfection for 48 h, the cells in each group were digested using the trypsin free of ethylene diamine tetraacetic acid (EDTA), collected in a flow tube, and centrifuged with the supernatant discarded. Following this, they were washed using cold PBS 3 times and centrifuged also with the supernatant eliminated. According to the instructions provided by the Annexin-V-fluorescein isothiocyanate (FITC) cell apoptosis kit (Sigma-Aldrich Chemical Company, St Louis MO, USA), the Annexin-V-FITC, PI, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer solution were made into the Annexin-V-FITC/PI dye (1:2:50). Every 100 µl of dye was used in order to suspend 1×10^6 cells, while the mixture was shaken evenly, incubated at room temperature for 15 min, added again with the HEPES buffer solution, and shaken evenly. The 525 nm and 620 nm band pass filter was used respectively for the FITC and PI fluorescence detection by the excitation wavelength of 488 nm in order to detect cell apoptosis.

Statistical Analysis

All data analyses were made using the SPSS 21.0 software (IBM Corp. Armonk, NY, USA). The measurement data was presented using the mean ± standard deviation. The t-test was used in order to test the comparison between two groups and

comparisons among multiple groups was made using the one-way analysis of variance (ANOVA). The $P < 0.05$ meant there was a statistically significant difference.

Results

Histopathological Changes of Cells in the Normal and Model Groups

The HE staining is shown as the Fig. 1. In comparison with the normal group, the model group had cells presented in various sizes, relative large volume, irregular shape, melanin granule in a few cytoplasm, a large amount of necrosis in tissue, and a few inflammatory cell infiltration in the melanoma mesenchyme and its adjacent tissue.

Higher LEF1 Positive Expression Rate in Cells of the Model Group

The immunohistochemistry staining is shown in the Fig. 2. The LEF1 positive expression was mainly located in the cytoplasm with the positive granule showing a brown-yellow color. The LEF1 positive expression rate in the normal group was $(20.31 \pm 5.28\%)$, which was significantly lower than that presented in the model group $[(65.35 \pm 6.85\%)]$ ($P < 0.05$).

Fig. 1 The histopathological changes of cells in the normal and model groups detected by the HE staining. Note: HE staining, hematoxylin-eosin staining





Fig. 2 The LEF1 positive expression in cells in the normal and model groups detected by the immunohistochemistry ($\times 200$). Note: *, $P < 0.05$, compared with the normal group; **a**, The immunohistochemistry staining




Fig. 3 The miR-708 expression and mRNA expressions of LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin in the normal and model groups. Note: *, $P < 0.05$, compared with the normal group; miR-708, microRNA-708; LEF1, lymphoid enhancer-binding factor-1; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated X protein

The miR-708 Expression and mRNA Expressions of LEF1, β -Catenin, Wnt3a, N-Cadherin, Bcl-2, Bax, Caspase3 and E-Cadherin in the Normal and Model Groups

The RT-qPCR results showed that, in comparison with the normal group, the model group had decreased miR-708

for the LEF1 positive expression; **b**, The histogram for the LEF1 positive expression in the normal and model groups; LEF1, lymphoid enhancer-binding factor-1




Fig. 4 The comparisons of protein expressions of LEF1, β-catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin in the normal and model groups. Note: **a**, The western blotting images for the protein expressions of the LEF1, β-catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin; **b**, The histogram for the protein expressions of the LEF1, β-catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin; *, $P < 0.05$, compared with the normal group; miR-708, microRNA-708; LEF1, lymphoid enhancer-binding factor-1; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated X protein

expression and mRNA expressions of Bax, Caspase3, and E-cadherin ($P < 0.05$) but increased mRNA expressions of LEF1, β-catenin, Bcl-2, Wnt3a, and N-cadherin (Fig. 3) ($P < 0.05$).

The Protein Expressions of LEF1, β-Catenin, Wnt3a, N-Cadherin, Bcl-2, Bax, Caspase3 and E-Cadherin in the Normal and Model Groups

The western blotting showed that, in comparison with the normal group, the model group had decreased levels of protein expressions between Bax, Caspase3, and E-cadherin ($P < 0.05$) but increased levels of protein expressions between LEF1, β-catenin, Bcl-2, Wnt3a, and N-cadherin (Fig. 4) ($P < 0.05$).

Fig. 5 LEF1 verified as the target gene of the miR-708. Note: **a**, The combination site of the miR-708 in the LEF1-3'UTR region; **b**, The luciferase activity; *, $P < 0.05$, compared with the NC group; NC, negative control; miR-708, microRNA-708; LEF1, lymphoid enhancer-binding factor-1

a mmu-miR-708/LEF1 Alignment

3'	ggGUCGAUCUACAUAUCGAGGAa	5'	mmu-miR-708	mirSVR score:	-0.8242
	::: :: :: :: :: :: :: :: :: ::			PhastCons score:	0.7303
6:5'	ggUGGUAAGA --G-AAGCUCCUu	3'	LEF1		





Fig. 6 Changes of miR-708 expression in the B16, A375, WM239 and WM451 cell lines. Note: *, $P < 0.05$, compared with the B16 cell line; miR-708, microRNA-708


LEF1 Was Verified as the Target Gene of miR-708

According to the online software analysis, the LEF1 gene sequence had a specific combination site in accordance to the miR-708 sequence, validating that LEF1 was indeed verified as the target gene of miR-708 (Fig. 5a), which was further confirmed by the use of the dual-luciferase reporter assay (Fig. 5b). The result showed that in comparison with the NC group, among the miR-708 mimic transfection groups, the WT-miR-708/LEF1 co-transfected group had decreased luciferase intensity ($P < 0.05$), while the mutant 3'UTR had no significant difference ($P > 0.05$), thus indicating that miR-708 can specifically bind to the LEF1.

B16 Cell Line Was Selected for Further Cell Experiments

The RT-qPCR was performed in order to detect the miR-708 expression of the B16, A375, WM239, and WM451 cell lines, and the cell line with the highest miR-708 expression was subsequently selected. The results demonstrated that the miR-708 presented different degrees of expression in the melanoma cell line (Fig. 6), among which the B16 cell line had the

Fig. 7 Comparisons of miR-708 expression and mRNA expressions of LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin after cell transfection in seven groups. Note: *, $P < 0.05$, compared with the control group; #, $P < 0.05$, compared with the blank and NC groups; NC, negative control; miR-708, microRNA-708; LEF1, lymphoid enhancer-binding factor-1; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated X protein



highest miR-708 expression ($P < 0.05$), and thus providing useful for further experimentation.

The miR-708 Expression and mRNA Expressions of LEF1, β -Catenin, Wnt3a, N-Cadherin, Bcl-2, Bax, Caspase3 and E-Cadherin after Cell Transfection in seven Groups

The RT-qPCR results showed that (Fig. 7), in comparison with the control group, the other groups had decreased levels of miR-708 expression and mRNA expressions between Bax, Caspase3, and E-cadherin ($P < 0.05$) but increased levels of mRNA expressions between LEF1, β -catenin, Bcl-2, Wnt3a, and N-cadherin ($P < 0.05$). There were no remarkable differences in the blank and NC groups ($P > 0.05$). In comparison

with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups had elevated levels of mRNA expressions between Bax, Caspase3, and E-cadherin ($P < 0.05$) but also reduced levels of mRNA expressions between LEF1, β -catenin, Bcl-2, Wnt3a, and N-cadherin ($P < 0.05$). The miR-708 mimic had increased levels of miR-708 expression ($P < 0.05$), and the siRNA-LEF1 group had shown no significant difference in miR-708 expression ($P > 0.05$). The miR-708 inhibitor group had decreased miR-708 expression and mRNA expressions of Bax, Caspase3, and E-cadherin ($P < 0.05$), but increased levels of mRNA expressions between LEF1, β -catenin, Bcl-2, Wnt3a and N-cadherin ($P < 0.05$). The miR-708 inhibitor + siRNA-LEF1 group had decreased miR-708 expression ($P < 0.05$), while no remarkable difference in the levels mRNA expressions between




Fig. 8 Comparisons of protein expressions of LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin after cell transfection in seven groups. Note: **a**, The western blotting images for the protein expressions of the LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3 and E-cadherin in seven groups; **b**, The histogram for the protein expressions of the LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2,

Bax, Caspase3 and E-cadherin in seven groups; *, $P < 0.05$, compared with the control group; #, $P < 0.05$, compared with the blank and NC groups; NC, negative control; miR-708, microRNA-708; LEF1, lymphoid enhancer-binding factor-1; Bcl-2, B cell lymphoma 2; Bax, Bcl-2-associated X protein





Fig. 9 The comparisons of cell proliferation ability after transfection in seven groups. Note: *, $P < 0.05$, compared with the control group (both 48 and 72 h); #, $P < 0.05$, compared with the blank and NC groups (both 48 and 72 h); NC, negative control

the LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3, and E-cadherin were detected ($P > 0.05$).

The Protein Expressions of LEF1, β -Catenin, Wnt3a, N-Cadherin, Bcl-2, Bax, Caspase3 and E-Cadherin after Cell Transfection in seven Groups

The western blotting results shown in Fig. 8, in comparison with the control group, the other groups had shown a decreased level of protein expressions between Bax, Caspase3, and E-cadherin ($P < 0.05$) but an increased level of protein expressions between LEF1, β -catenin, Bcl-2, Wnt3a, and N-cadherin ($P < 0.05$). There were also no remarkable differences found in the blank and NC groups ($P > 0.05$). In comparison with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups had found elevated levels of protein expressions between Bax, Caspase3, and E-cadherin ($P < 0.05$) but also reduced levels of protein expressions between LEF1, β -catenin, Bcl-2, Wnt3a, and N-cadherin

Fig. 10 The comparisons of cell migration ability after transfection in seven groups. Note: **a**, The cell scratch space after cell transfection in seven groups; **b**, The histogram for the distance of migration after transfection in seven groups; *, $P < 0.05$, compared with the blank and NC groups; NC, negative control



($P < 0.05$). The miR-708 inhibitor group had decreased protein expressions of Bax, Caspase3 and E-cadherin ($P < 0.05$), but increased protein expressions of LEF1, β -catenin, Bcl-2, Wnt3a and N-cadherin ($P < 0.05$). The miR-708 inhibitor + siRNA-LEF1 group had shown no remarkable differences in the protein expressions of LEF1, β -catenin, Wnt3a, N-cadherin, Bcl-2, Bax, Caspase3, and E-cadherin ($P > 0.05$).

Overexpression of miR-708 or siRNA-LEF1 Inhibits Cell Proliferation

In comparison with the control group, the blank, NC, miR-708 mimic, siRNA-LEF1, and miR-708 inhibitor groups all had elevated OD value at 48 h and 72 h after cell transcription (all $P < 0.05$). In comparison with the blank and NC groups, the miR-708 inhibitor group had elevated OD value at 48 h and 72 h after cell transcription (all $P < 0.05$), the miR-708 mimic and siRNA-LEF1 groups had decreased OD value at 48 h and 72 h after cell transcription (all $P < 0.05$), and the miR-708 inhibitor + siRNA-LEF1 group had shown no significant differences ($P > 0.05$) (Fig. 9).

Overexpression of miR-708 or siRNA-LEF1 Inhibits Cell Migration

There were no remarkable differences in cell migration ability between the blank and NC groups ($P > 0.05$). In comparison with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups both had decreased cell migration ability (all $P < 0.05$), the miR-708 inhibitor group had an elevated cell migration ability (all $P < 0.05$), and the miR-708 inhibitor + siRNA-LEF1 group had again shown no significant differences ($P > 0.05$) (Fig. 10).

Overexpression of miR-708 or siRNA-LEF1 Inhibits Cell Invasion

There were no remarkable differences in cell invasion abilities between the blank and NC groups ($P > 0.05$). In comparison




Fig. 11 The comparisons of cell invasion ability after transfection in seven groups. Note: **a**, The cell invasion image after cell transfection in seven groups; **b**, The histogram for the comparisons of cell invasion

ability after transfection in seven groups; *, $P < 0.05$, compared with the blank and NC groups; NC, negative control

with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups had decreased cell invasion abilities (all $P < 0.05$), the miR-708 inhibitor group had an elevated cell invasion ability (all $P < 0.05$), and the miR-708 inhibitor + siRNA-LEF1 group had again shown no significant differences ($P > 0.05$) (Fig. 11).

(elevated cell number in S phase) (all $P < 0.05$). In comparison with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups both had lengthened G0/G1 phase (decreased cell number in G0/G1 phase) but a shortened S phase (elevated cell number in S phase) (all $P < 0.05$), the miR-708 inhibitor group had a shortened G0/G1 phase (decreased cell number in G0/G1 phase) but a lengthened S phase (elevated cell number in S phase) (all $P < 0.05$), and the miR-708 inhibitor + siRNA-LEF1 group had again shown no significant differences ($P > 0.05$) (Fig. 12).

Decreased Cell Number in G0/G1 Phase and Elevated Cell Number in S Phase in the miR-708 Mimic and siRNA-LEF1 Groups

Overexpression of miR-708 or siRNA-LEF1 Promotes Cell Apoptosis

In comparison with the control group, the blank, NC, miR-708 mimic, siRNA-LEF1, miR-708 inhibitor, and miR-708 inhibitor + siRNA-LEF1 groups all had shortened G0/G1 phase (decreased cell number in G0/G1 phase) but a lengthened S phase

In comparison with the control group, the blank, NC, miR-708 mimic, siRNA-LEF1, miR-708 inhibitor and miR-708




Fig. 12 Changes of cell cycle distribution after transfection in seven groups. Note: **a**, The cell cycle image after cell transfection in seven groups; **b**, The histogram for the comparisons of cell cycle ratio after

transfection in seven groups; *, $P < 0.05$, compared with the control group; #, $P < 0.05$, compared with the blank and NC groups; NC, negative control




Fig. 13 The cell apoptosis after transfection in seven groups. Note: **a**, The cell apoptosis image after cell transfection in seven groups; **b**, The histogram for the comparisons of cell apoptosis ratio after transfection in

seven groups; *, $P < 0.05$, compared with the control group; #, $P < 0.05$, compared with the blank and NC groups; NC, negative control

inhibitor + siRNA-LEF1 groups had all successively decreased cell apoptosis ($P < 0.05$). In comparison with the blank and NC groups, the miR-708 mimic and siRNA-LEF1 groups both had increased cell apoptosis (all $P < 0.05$), the miR-708 inhibitor group had declined cell apoptosis (all $P < 0.05$), and the miR-708 inhibitor + siRNA-LEF1 group had shown no significant differences ($P > 0.05$) (Fig. 13).

Discussion

There have been previous studies reporting that miR-708 plays distinctive roles in several types of cancers. In renal cancer cells, elevation of miR-708 induces cell apoptosis and suppresses tumorigenicity, but in lung adenocarcinoma the elevation of miR-708 expression correlates with a poor prognosis [13, 20]. Therefore, the concrete function and effect of miR-708 may depend on differing cell types. In this study, we aimed to explore how various action modes of miR-708 affect proliferation, EMT, and apoptosis of melanoma cells. We believed its target LEF1 and the Wnt signaling pathway may also play a role in the function regarding this progress.

Initially, our results indicated miR-708 induced EMT and cell apoptosis, and reduced proliferation, migration, and invasion as a tumor suppressor in melanoma. The miR-708 expression suppresses the breast cancer metastasis through inhibition of neuronatin in endoplasmic reticulum membranes, reduces intracellular calcium, and decreases extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK) [21]. Reports from Pérez et al. and Zhuang et al. found that B16 cells, a murine melanoma cell line, exhibited markedly up-regulated phosphorylation of ERK and its inhibition impaired the increased metastatic behavior of B16 [22, 23].

Also, Hess et al. supported the notion that the inhibition of FAK suppresses the aggressive melanoma phenotype [24]. MiR-708 is also reported to play a critical role in suppressing the development of glioblastoma and downregulating Akt1 and CCND1, both of which promote the proliferation of cancer cells also EZH2 and MMP2, both of which contribute to the invasion of cancer cells [25]. Cho et al. also reported that AKT1 activation facilitates development of melanoma metastases [26] and Vizkeleti et al. found that alterations made of CCND1 gene expression may affect the metastatic progression, survival rate, and the localization of metastases in melanoma [27]. In addition, several studies stated that NF- κ B2 retards cell senescence in melanoma through a direct transcriptional activation of EZH2 and that the expression of MMP-2 inhibition might contribute in the progression of the melanoma [28, 29]. Judgin by these findings and reports, we believed miR-708 plays an anti-tumor role in melanoma.

Essentially, we demonstrated that the function of miR-708 influencing melanoma cells can be achieved by targeting LEF1 by way of the Wnt signaling pathway. The LEF1 was predicted as the target gene of miR-708 by the data found on [microRNA.org](http://www.microrna.org) and verified using dual-luciferase reporter gene assay (<http://www.microrna.org>). A recent study also revealed that LEF1 promotes EMT related invasion in prostate cancer, while that study didn't explore the mechanism adjusted, particularly, by MiRs [30]. LEF1 is a pivotal transcription factor in the Wnt pathway, which has been indicated to be involved with in both cell proliferation and invasion [31]. LEF1 is found to be expressed in the hippocampal neural stem cells reacting in accordance with the activation of the Wnt signaling pathway [32]. A previous study indicates that the Wnt pathway is implicated in melanoma [33]. The Wnt pathway contributes to controlling

of the cancer progression and performs as a key element in the initiation of EMT [34]. E-cadherin coordinating EMT is a key embryonic process that is re-triggered during the process of tumorigenesis [13]. The central event for the development of malignant melanoma is the loss of the tumor-suppressor protein, E-cadherin [35]. Moreover, on the endothelium, attachment of melanoma cells can trigger a two-fold increase in the N-cadherin expression and along with, an increase in β -catenin nuclear level in melanoma cells [36]. Consistent with our results, several studies supported the targeting of the Wnt/ β -catenin pathway could be an alternative therapeutic approach for treating melanoma [33, 37].

Thus, we could make the conclusion that expression of miR-708 could inhibit the EMT of melanoma cells by targeting LEF1 through the Wnt signaling pathway.

In conclusion, our findings demonstrated that overexpression of miR-708 in melanoma B16 cells significantly suppresses the proliferation and EMT, but enhances apoptosis of the melanoma cells by targeting LEF1 through suppression of the Wnt signaling pathway. Therefore, this study laid a solid theoretical foundation for understanding the molecular mechanism between melanoma growth and finding new molecular targets for the treatment of melanoma.

Acknowledgements We would like to acknowledge the helpful comments on this paper received from our reviewers.

Compliance with Ethical Standards

Conflict of Interest None.

References

1. Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, Hainaut P, Charles J (2017) Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. *Biomed Res Int* 2017:5986129
2. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, CJ W, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 499:214–218
3. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. *CA Cancer J Clin* 67:7–30
4. Miller AJ, Mihm MC Jr (2006) Melanoma. *N Engl J Med* 355:51–65
5. Wu S, Singh RK (2011) Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. *Curr Mol Med* 11:553–563
6. Melis C, Rogiers A, Bechter O, van den Oord JJ (2017) Molecular genetic and immunotherapeutic targets in metastatic melanoma. *Virchows Arch*. <https://doi.org/10.1007/s00428-017-2113-3>
7. Ndoye A, Weeraratna AT (2016) Autophagy- an emerging target for melanoma therapy. *F1000research* 5:1888
8. Lelli D, Pedone C, Sahebkar A (2017) Curcumin and treatment of melanoma: the potential role of microRNAs. *Biomed Pharmacother* 88:832–834
9. Sun V, Zhou WB, Majid S, Kashani-Sabet M, Dar AA (2014) MicroRNA-mediated regulation of melanoma. *Br J Dermatol* 171:234–241
10. Luo C, Weber CE, Osen W, Bosserhoff AK, Eichmüller SB (2014) The role of microRNAs in melanoma. *Eur J Cell Biol* 93:11–22
11. Leibowitz-Amit R, Sidi Y, Avni D (2012) Aberrations in the microRNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma. *Pigment Cell Melanoma Res* 25:740–757
12. Li G, Yang F, Xu H, Yue Z, Fang X, Liu J (2015) MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. *Biomed Pharmacother* 73:154–159
13. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, Dahiya R (2011) MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. *Cancer Res* 71:6208–6219
14. Lin KT, Yeh YM, Chuang CM, Yang SY, Chang JW, Sun SP, Wang YS, Chao KC, Wang LH (2015) Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. *Nat Commun* 6:5917
15. Murakami T, Saitoh I, Sato M, Inada E, Soda M, Oda M, Domon H, Iwase Y, Sawami T, Matsueda K, Terao Y, Ohshima H, Noguchi H, Hayasaki H (2017) Isolation and characterization of lymphoid enhancer factor-1-positive deciduous dental pulp stem-like cells after transfection with a piggyBac vector containing LEF1 promoter-driven selection markers. *Arch Oral Biol* 81:110–120
16. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H (2014) Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. *Nat Commun* 5:5694
17. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell* 18:683–695
18. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT (2013) Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. *Cancer Discov* 3:1378–1393
19. Ayuk SM, Abrahamse H, Hourelid NN (2016) The role of photobiomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro. *J Photochem Photobiol B* 161:368–374
20. Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J (2012) Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. *Clin Cancer Res* 18:3658–3667

21. Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB, Mittal V (2013) Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. *Cancer Cell* 23:63–76
22. Perez EC, Machado J Jr, Aliperti F, Freymuller E, Mariano M, Lopes JD (2008) B-1 lymphocytes increase metastatic behavior of melanoma cells through the extracellular signal-regulated kinase pathway. *Cancer Sci* 99:920–928
23. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P (2005) Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. *J Clin Pathol* 58:1163–1169
24. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ (2005) Focal adhesion kinase promotes the aggressive melanoma phenotype. *Cancer Res* 65:9851–9860
25. Guo P, Lan J, Ge J, Nie Q, Mao Q, Qiu Y (2013) miR-708 acts as a tumor suppressor in human glioblastoma cells. *Oncol Rep* 30:870–876
26. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL (2015) AKT1 activation promotes development of melanoma metastases. *Cell Rep* 13:898–905
27. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, Emri G, Koroknai V, Kiss T, Adany R, Balazs M (2012) The role of CCND1 alterations during the progression of cutaneous malignant melanoma. *Tumour Biol* 33:2189–2199
28. De Donatis GM, Pape EL, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T (2016) NF- κ B2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. *Oncogene* 35:2735–2745
29. Redondo P, Lloret P, Idoate M, Inoges S (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. *Clin Exp Dermatol* 30:541–545
30. Wu L, Zhao JC, Kim J, Jin HJ, Wang CY, Yu J (2013) ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. *Cancer Res* 73:6068–6079
31. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, Melamed J, Zhao J, Lee P (2015) LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. *Mol Cancer Res* 13:681–688
32. Cui XP, Xing Y, Chen JM, Dong SW, Ying DJ, Yew DT (2011) Wnt/beta-catenin is involved in the proliferation of hippocampal neural stem cells induced by hypoxia. *Ir J Med Sci* 180:387–393
33. Castiglia D, Bernardini S, Alvino E, Pagani E, De Luca N, Falcinelli S, Pacchiarotti A, Bonmassar E, Zambruno G, D'Atri S (2008) Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. *Genes Chromosom Cancer* 47:614–624
34. Sun L, Liu T, Zhang S, Guo K, Liu Y (2017) Oct4 induces EMT through LEF1/beta-catenin dependent WNT signaling pathway in hepatocellular carcinoma. *Oncol Lett* 13:2599–2606
35. Spangler B, Vardimon L, Bosserhoff AK, Kuphal S (2011) Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma. *Pigment Cell Melanoma Res* 24:148–164
36. Qi J, Chen N, Wang J, Siu CH (2005) Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. *Mol Biol Cell* 16:4386–4397
37. Chen H, Gao X, Sun Z, Wang Q, Zuo D, Pan L, Li K, Chen J, Chen G, Hu K, Li K, Shah AS, Huang T, Zeeshan Bhatti M, Tong L, Jiao C, Liu J, Chen T, Yao L, Dang Y, Liu T, Li L (2017) REGgamma accelerates melanoma formation by regulating Wnt/beta-catenin signaling pathway. *Exp Dermatol* 26:1118–1124